Clinical Trial Update: Study Investigating the Safety of CD19 CAR-T Cells in Relapsed/Refractory AML Expressing CD19 [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is investigating the safety of CD19 CAR-T cells in patients with relapsed or refractory acute myeloid leukemia that expresses CD19. The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CD19 CAR T cells

Snippet

Sponsor: University Hospital, Lille | Conditions: Relapsed Adult AML | Phase 1 | Status: RECRUITING